Author of the publication

The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma

, , , , , , , , , , , and . J Cancer Res Clin Oncol, 142 (8): 1825-1829 (August 2016)
DOI: 10.1007/s00432-016-2187-3

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Unsupervised consensus cluster analysis of 18F-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma, , , , , , , , , and . Oncotarget, 8 (5): 8294-8304 (January 2017)Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide, , , , , , , , , and 4 other author(s). J Clin Oncol, 30 (21): 180-183 (July 2012)Phase I trial of dovitinib (TKI258) in recurrent glioblastoma, , , , , , , , , and 7 other author(s). J Cancer Res Clin Oncol, 142 (7): 1581-1589 (July 2016)Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma, , , , , , , , , and 1 other author(s). Cancer Med, 6 (1): 89-99 (January 2017)The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma, , , , , , , , , and 2 other author(s). J Cancer Res Clin Oncol, 142 (8): 1825-1829 (August 2016)Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma, , , , , , , , , and 12 other author(s). Stem Cells, 31 (6): 1064-1074 (June 2013)